GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (STU:0Z2) » Definitions » Notes Receivable

Alector (STU:0Z2) Notes Receivable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alector Notes Receivable?

Alector's Notes Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.


Alector Notes Receivable Historical Data

The historical data trend for Alector's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Notes Receivable Chart

Alector Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Alector Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alector Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Alector Notes Receivable Related Terms

Thank you for viewing the detailed overview of Alector's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Alector Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector Headlines

No Headlines